Molecular alterations leading to active phosphatidylinositol 3-kinase (PI3K) signaling (loss of PTEN and PIK3CA/B mutations) are among the most frequent events in metastatic prostate cancer occurring in greater than 60% of tumor specimens (1–3). This evidence concerns the gene PIK3CA and metastatic prostate carcinoma.